Product Information
DISOPYRAMIDE 150 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.5318 per EA under NDC 00093312901. Its NADAC has been published 650 times since Nov 28, 2013.
FDA first approved this application on Feb 22, 1985. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093312901
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DISOPYRAMIDE PHOSPHATEApproval Type
Generic (ANDA)
FDA Application
ANDA070102FDA Approved
2/22/1985
TE Code
AB
On Market Since
9/30/1990
Pharmacological Classes
Price Statistics
The NADAC for DISOPYRAMIDE 150 MG CAPSULE has been published 650 times since Nov 28, 2013, and over the history we have for it it has risen 406.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5318 per EA |
|---|---|
| All-time high | $1.8360 (May 15, 2019) |
| All-time low | $0.2919 (Sep 17, 2014) |
| 52-week high | $1.7091 |
| 52-week low | $1.4907 |
| Median price | $1.4743 |
| Average price | $1.3423 |
| Largest weekly change | +203.5% (Apr 20, 2016) |
| Weeks tracked | 650 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Disopyramide Phosphate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Disopyramide Phosphate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DISOPYRAMIDE 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DISOPYRAMIDE 150 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $1.5318 per EA (NDC 00093312901), effective Sep 30, 2026.
How has the price of DISOPYRAMIDE 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DISOPYRAMIDE 150 MG CAPSULE has risen 406.8%. It has been tracked across 650 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DISOPYRAMIDE 150 MG CAPSULE?
Since Nov 28, 2013, the NADAC for DISOPYRAMIDE 150 MG CAPSULE has ranged from a low of $0.2919 (Sep 17, 2014) to a high of $1.8360 (May 15, 2019), with a median of $1.4743 per EA.
Are there cheaper alternatives to DISOPYRAMIDE 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of DISOPYRAMIDE 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DISOPYRAMIDE 150 MG CAPSULE?
DISOPYRAMIDE 150 MG CAPSULE (NDC 00093312901) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.